Gene · 64761
Papers1,639
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,639
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Abstracts Presented at the 2024 WIN Symposium in Partnership with Burjeel Holdings: March 1-2, 2024, Abu Dhabi, United Arab Emirates. | J Immunother Precis Oncol | 2024 | 39219997 | PubTator, text mining | PubMed |
| Leveraging PARP-1/2 to Target Distant Metastasis. | Int J Mol Sci | 2024 | 39201718 | PubTator, text mining | PubMed |
| CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos. | Int J Mol Sci | 2024 | 39201277 | PubTator, text mining | PubMed |
| PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology. | Expert Rev Mol Med | 2024 | 39189367 | PubTator, text mining | PubMed |
| The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models. | Genome Med | 2024 | 39187844 | PubTator, text mining | PubMed |
| Regulation of PARP1/2 and the tankyrases: emerging parallels. | Biochem J | 2024 | 39178157 | PubTator, text mining | PubMed |
| Dispensability of HPF1 for cellular removal of DNA single-strand breaks. | Nucleic Acids Res | 2024 | 39162207 | PubTator, text mining | PubMed |
| Carbamoylation at C-8 position of natural 3-arylcoumarin scaffold for the discovery of novel PARP-1 inhibitors with potent anticancer activity. | Eur J Med Chem | 2024 | 39116535 | PubTator, text mining | PubMed |
| SMARCA2 and SMARCA4 Participate in DNA Damage Repair. | Front Biosci (Landmark Ed) | 2024 | 39082357 | PubTator, text mining | PubMed |
| Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells. | Nat Commun | 2024 | 39068174 | PubTator, text mining | PubMed |
| Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors. | Cancer Med | 2024 | 38970256 | PubTator, text mining | PubMed |
| Identification of Poly(ADP-ribose) Polymerase 9 (PARP9) as a Potent Suppressor for Mycobacterium tuberculosis Infection. | Phenomics | 2024 | 38884060 | PubTator, text mining | PubMed |
| CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer. | Cell Death Discov | 2024 | 38862485 | PubTator, text mining | PubMed |
| RNA Sequencing Analyses Reveal the Potential Anti-Inflammatory Mechanisms of Acacetin Against ODG/R Injuries in Microglia. | J Inflamm Res | 2024 | 38855167 | PubTator, text mining | PubMed |
| Comprehensive analysis of the functions, prognostic and diagnostic values of RNA binding proteins in head and neck squamous cell carcinoma. | J Stomatol Oral Maxillofac Surg | 2024 | 38844022 | PubTator, text mining | PubMed |
| Identification of Potential Ferroptosis Biomarkers and Analysis of Immune Cell Infiltration in Psoriasis Using Machine Learning. | Clin Cosmet Investig Dermatol | 2024 | 38835517 | PubTator, text mining | PubMed |
| The loss of DNA polymerase epsilon accessory subunits POLE3-POLE4 leads to BRCA1-independent PARP inhibitor sensitivity. | Nucleic Acids Res | 2024 | 38828775 | PubTator, text mining | PubMed |
| Improving olaparib exposure to optimize adverse effects management. | Ther Adv Med Oncol | 2024 | 38665845 | PubTator, text mining | PubMed |
| PTIP UFMylation promotes replication fork degradation in BRCA1-deficient cells. | J Biol Chem | 2024 | 38657865 | PubTator, text mining | PubMed |
| Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial. | Radiat Oncol | 2024 | 38610031 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64761/papers?page=6